Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)

Phase 2

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Revlimid
Drug: Velcade
Drug: dexamethasone
Drug: Farydak

First Posted Date: 2016-03-28

Last Posted Date: 2018-07-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 6

Registration Number: NCT02720510

Locations: 🇺🇸
David Geffen School of Medicine at UCLA UCLA, Los Angeles, California, United States
🇺🇸
Northside Hospital Central Research Dept., Atlanta, Georgia, United States
🇺🇸
Oncology Hematology West Nebraska Cancer Specialists dbaNebraska Cancer Specialists, Omaha, Nebraska, United States

and more 2 locations

Extended Evaluation of Deferasirox Film-coated Tablet (FCT) Formulation

Phase 3

Completed

Conditions: Chronic Iron Overload

Interventions: Drug: Deferasirox

First Posted Date: 2016-03-28

Last Posted Date: 2020-03-03

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 53

Registration Number: NCT02720536

Locations: 🇮🇹
Novartis Investigative Site, Napoli, Italy

Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01)

Phase 4

Completed

Conditions: Relapsing-remitting Multiple Sclerosis

Interventions: Drug: fingolimod

First Posted Date: 2016-03-25

Last Posted Date: 2019-02-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 133

Registration Number: NCT02720107

Locations: 🇩🇪
Novartis Investigative Site, Unterhaching, Germany

Safety and Exploratory Efficacy of HSC835 in Patients With Inherited Metabolic Disorders (IMD)

Phase 1

Withdrawn

Conditions: Inherited Metabolic Disorders IMD

Interventions: Drug: Umbilical cord blood transplantation with HSC835

First Posted Date: 2016-03-22

Last Posted Date: 2018-11-28

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT02715505

Dose-finding Study to Assess the Efficacy, Safety and Tolerability of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection

Phase 2

Completed

Conditions: Non-cystic Fibrosis Bronchiectasis

Interventions: Drug: TIP
Drug: TIP and placebo
Drug: Placebo

First Posted Date: 2016-03-18

Last Posted Date: 2020-08-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 107

Registration Number: NCT02712983

Locations: 🇬🇧
Novartis Investigative Site, Southampton, United Kingdom

A Study to Evaluate the Safety and Effect of CFZ533 on Patients With Graves' Disease

Phase 2

Completed

Conditions: Graves' Disease

Interventions: Drug: CFZ533

First Posted Date: 2016-03-18

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 15

Registration Number: NCT02713256

Locations: 🇩🇪
Novartis Investigative Site, Mainz, Germany

To Assess Safety, Tolerability and Efficacy of LJN452 in Patients With Primary Bile Acid Diarrhea.

Phase 2

Completed

Conditions: Primary Bile Acid Diarrhea

Interventions: Drug: LJN452
Drug: Placebo to LJN452

First Posted Date: 2016-03-18

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 20

Registration Number: NCT02713243

Locations: 🇬🇧
Novartis Investigative Site, Sheffield, United Kingdom

A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.

Phase 1

Terminated

Conditions: Ovarian Neoplasms
Non-Small-Cell Lung Carcinoma
Melanoma
Other Solid Tumors

Interventions: Drug: LTT462

First Posted Date: 2016-03-17

Last Posted Date: 2019-09-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 65

Registration Number: NCT02711345

Locations: 🇨🇭
Novartis Investigative Site, Bellinzona, Switzerland

A Drug-Drug Interaction Study to Assess the Effect of Trametinib on the Pharmacokinetics of an Oral Contraceptive in Female Patients With Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: Trametinib
Drug: Oral Contraceptive (1mg norethindrone, 0.035mg ethinyl estradiol)

First Posted Date: 2016-03-11

Last Posted Date: 2022-02-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 19

Registration Number: NCT02705963

Locations: 🇺🇸
University of Oklahoma, Oklahoma City, Oklahoma, United States
🇺🇸
Karmanos Cancer Institute Karmanos Cancer Institute, Detroit, Michigan, United States
🇬🇧
Novartis Investigative Site, London, United Kingdom

Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors

Phase 1

Terminated

Conditions: Solid Tumors for Phase Ib
Pancreatic Cancer for Phase II
Colorectal Cancer for Phase II

Interventions: Drug: ribociclib
Drug: Trametinib

First Posted Date: 2016-03-09

Last Posted Date: 2020-12-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 95

Registration Number: NCT02703571

Locations: 🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States
🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸
Dana Farber Cancer Center, Boston, Massachusetts, United States

and more 4 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy